Efficacy of the 7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline derivative against infection caused by Leishmania amazonensis
Rev. Soc. Bras. Med. Trop
;
53: e20200091, 2020. graf
Article
in English
| SES-SP, ColecionaSUS, LILACS
| ID: biblio-1136875
ABSTRACT
Abstract INTRODUCTION:
The drugs currently available for leishmaniasis treatment have major limitations.METHODS:
In vitro and in vivo studies were performed to evaluate the effect of a quinoline derivative, Hydraqui (7-chloro-4-(3-hydroxy-benzilidenehydrazo)quinoline, against Leishmania amazonensis. In silico analyses of absorption, distribution, metabolism, excretion, and toxicity (ADMET) parameters were performed.RESULTS:
Hydraqui showed significant in vitro anti-amastigote activity. Also, Hydraqui-treated mice exhibited high efficacy in lesion size (48.3%) and parasitic load (93.8%) reduction, did not cause hepatic and renal toxicity, and showed appropriate ADMET properties.CONCLUSIONS:
Hydraqui presents a set of satisfactory criteria for its application as an antileishmanial agent.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Quinolines
/
Leishmania mexicana
/
Leishmaniasis, Cutaneous
/
Antiprotozoal Agents
Type of study:
Prognostic study
Limits:
Animals
Language:
English
Journal:
Rev. Soc. Bras. Med. Trop
Year:
2020
Type:
Article
Institution/Affiliation country:
Fundação Oswaldo Cruz/BR
/
Universidade Federal de Juiz de Fora/BR
/
Universidade Federal de Minas Gerais/BR
/
Universidade Federal do Rio de Janeiro/BR
Similar
MEDLINE
...
LILACS
LIS